The Relationship of Androgenic Alopecia and Opium Consumption in Men: A Comparative Study

Document Type : Original Article (s)

Authors

1 General Practitioner, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Community Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student of Medicine, Student Research Committee, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

5 PharmD, Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

6 Assistant Professor, Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

Abstract

Background: Androgenic alopecia (AGA) is one of the most common problems among men; in some societies, 50 percent of 50-years-old men are involved. In the past, opium versions of therapeutic compounds for the treatment of hair loss were used. Therefore, this study aimed to examine the relationship of opium consumption and androgenic alopecia in men.Methods: In this case-control study, 604 men referred to the Isfahan Amin Hospital, Iran, were enrolled. The sampling method was a simple classification (convenient) and men were divided to 2 equal groups of control (non-consumer of opium) and addict (consumer of opium). The intensity of androgenic alopecia was compared on the basis of a Hamilton Norwood scale. Data were collected using physical examination and a researcher-made questionnaire. Statistical analysis was carried using chi-square, Student's t, Spearman and One-way ANOVA tests.Findings: Percentage frequency of androgenic alopecia in addict men was significantly less than control group (P < 0.001). In addition, the intensity of androgenic alopecia had significant inverse relationship with the amount of opium consumption per year in the distinct range (P < 0.001).Conclusion: Our finding indicates that the prevalence of androgenic alopecia in opium-addict men is lower than non-consumer men.

Keywords

References

  1. Qi J, Garza LA. An overview of alopecias. Cold Spring Harb Perspect Med 2014; 4(3): a013615.
  2. Wolff FC, Johnson R. Disorders of hair follicles and related disorders. In: Wolff FC, Johnson R, editors. Fitzpatrick's color atlas and synopsis of clinical. New York, NY: McGraw Hill; 2009.
  3. Jaffary F, Nilforoushzadeh MA, Haftbaradaran E. Review on using platelet rich plasma in hair loss and hair transplantation. J Isfahan Med Sch 2015; 33(339): 970-8. [In Persian].
  4. Batrinos ML. The endocrinology of baldness. Hormones (Athens) 2014; 13(2): 197-212.
  5. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol 2001; 19(2): 167-78.
  6. Banka N, Bunagan MJ, Shapiro J. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin 2013; 31(1): 129-40.
  7. Nilforoushzadeh MA, Haftbaradaran E, Hoseini SM, Ahmadian N, Zolfaghai-Baghbaderani A. Evaluating the success rate of follicular unit hair transplantation (FUT) technique in patients with gray hair. J Isfahan Med Sch 2015; 33(356): 1820-8. [In Persian].
  8. Iraji F, Hosseini SM, Siadat AH, Nilforoushzadeh MA, Mashhadi Z. Comparing the efficiency of combination of minoxidil solution and tacrolimus cream with minoxidil solution alone in the treatment of alopecia areata. J Isfahan Med Sch 2014; 31(269): 2315-25. [In Persian].
  9. Mokhtari F, Fatemi-Naeini F, Panjehpour T, Hosseini SM, Nilforoushzadeh MA. Evaluation of anti-tissue-trans glutamines IgA in alopecia areata. J Isfahan Med Sch 2016; 34(379): 381-6. [In Persian].
  10. Allahtavakoli M, Moloudi R, Rezvani ME, Shamsizadeh A. Effect of morphine withdrawal syndrome on cerebral ischemia outcome in rats. Iran J Basic Med Sci 2011; 14(1): 1-8.
  11. Ghasemi F, Moradi A, Izadpanah E, Moloudi MR, Hassanzadeh K, Rahimmi A, et al. Simvastatin prevents morphine antinociceptive tolerance and withdrawal symptoms in rats. J Formos Med Assoc 2015; 114(5): 399-406.
  12. Amini H, Izadpanah E, Raman Moloudi M, Hassanzadeh K. Effect of systemic administration of mefloquine on morphine-induced withdrawal symptoms in rats. J Mazandaran Univ Med Sci 2015; 24(121): 86-93. [In Persian].
  13. Zanjani B, Moloudi MR, Izadpanah E, Hassanzadeh K. Effect of methylphenidate on methadone-induced analagesia in rat. J Isfahan Med Sch 2015; 33(327): 316-25. [In Persian].
  14. Zaidi Z, Lanigan SW. Hair disorders. In: Zaidi Z, Lanigan SW, editors. Dermatology in clinical practice. New York, NY: Springer; 2010. p. 359-80.
  15. Lascaratos J, Tsiamis C, Lascaratos G, Stavrianeas NG. The roots of cosmetic medicine: hair cosmetics in Byzantine times (AD 324-1453). Int J Dermatol 2004; 43(5): 397-401.
  16. Kauser S, Thody AJ, Schallreuter KU, Gummer CL, Tobin DJ. Beta-Endorphin as a regulator of human hair follicle melanocyte biology. J Invest Dermatol 2004; 123(1): 184-95.
  17. Canyon SJ, Dobson GP. Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am J Physiol Heart Circ Physiol 2004; 287(3): H1286-H1295.
  18. Bali A, Randhawa PK, Jaggi AS. Stress and opioids: role of opioids in modulating stress-related behavior and effect of stress on morphine conditioned place preference. Neurosci Biobehav Rev 2015; 51: 138-50.
  19. van Beek N, Bodo E, Kromminga A, Gaspar E, Meyer K, Zmijewski MA, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab 2008; 93(11): 4381-8.
  20. Zhang X, Yu M, Yu W, Weinberg J, Shapiro J, McElwee KJ. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. J Invest Dermatol 2009; 129(6): 1527-38.
  21. Zhang GF, Tang YL, Smith AK, Liu ZQ, Sheng LX, Chi Y, et al. Clinical study: Alterations in pituitary-thyroid axis function among opioid-dependent subjects after acute and protracted abstinence. Addict Biol 2009; 14(3): 310-4.
  22. Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend 2015; 149: 1-9.
  23. Cyrus A, Solhi H, Azizabadi FM, Khoddami Vishteh HR, Goudarzi D, Mosayebi G, et al. The effect of opium dependency on testis volume: a case-control study. Iran J Reprod Med 2012; 10(6): 517-22.
  24. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3(5): 377-84.
  25. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85(6): 2215-22.
  26. Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci 2004; 34(1): 11-6.
  27. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116(3): 452-5.
  28. Muller DC, Giles GG, Sinclair R, Hopper JL, English DR, Severi G. Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2013; 22(2): 209-15.
  29. Aloisi AM, Ceccarelli I, Fiorenzani P, Maddalena M, Rossi A, Tomei V, et al. Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats. Mol Pain 2010; 6: 69.
Journal of Isfahan Medical School
Volume 34, Issue 407 - Serial Number 407
September and October 2017
Pages 1375-1380

Files

History

  • Receive Date: 04 September 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics